Federal authorities on Wednesday sanctioned Eli Lilly’s novel oral pharmaceutical agent for weight management, marking a significant development as the second daily oral therapeutic option available for addressing obesity and associated weight-related health concerns.
The Food and Drug Administration has granted accelerated clearance for orforglipron, a drug belonging to the GLP-1 class. This medication functions comparably to established injectable treatments by emulating a naturally occurring hormone responsible for regulating satiety and appetite.
The pharmaceutical compound, which will be marketed under the brand name Foundayo, is anticipated to be available for distribution starting next Monday. The manufacturer indicated that individuals with comprehensive insurance coverage might be able to procure the medication for as little as $25 per month with the assistance of a Lilly discount voucher. For patients opting for out-of-pocket payment, the monthly cost is projected to range between $149 and $349, contingent upon the prescribed dosage.
This newly approved oral agent joins Novo Nordisk’s oral formulation of Wegovy, a medication that has already generated substantial demand, evidenced by the issuance of over 600,000 prescriptions in the United States following its regulatory approval in December.
The FDA’s authorization of Eli Lilly’s therapeutic is a component of an innovative program designed to expedite the drug review and approval timeline. The agency confirmed that the company’s submission underwent review in a period of 50 days.
Findings from a clinical investigation involving over 3,000 adults diagnosed with obesity, published in the New England Journal of Medicine, revealed that participants who received the highest dosage of orforglipron (36 milligrams) experienced an average body weight reduction of 11.2%, equivalent to approximately 25 pounds over a duration exceeding 16 months.
In contrast, individuals administered a placebo, or an inactive substance, demonstrated a mere 2.1% decrease in body weight, which equated to less than 5 pounds on average.
However, both the oral formulations from Lilly and Novo Nordisk have shown a lower average weight loss compared to the efficacy of Lilly’s injectable drug, Zepbound, which has resulted in an average weight loss of 21%, and Novo Nordisk’s injectable Wegovy, which averages around 15% weight reduction.
While both once-daily oral medications offer unparalleled convenience, orforglipron, distinguished as a small-molecule GLP-1 drug, provides enhanced flexibility as it can be taken without specific consumption restrictions.
Conversely, the Wegovy pill, a peptide-based formulation, necessitates specific administration guidelines: it must be taken with a small amount of water in the morning on an empty stomach, followed by a 30-minute waiting period before consuming any food or beverages.
Further analysis from the study indicated that individuals utilizing orforglipron also exhibited improvements in key health markers, including waist circumference, blood pressure, triglyceride levels, and cholesterol profiles.
Adverse effects, predominantly gastrointestinal disturbances, prompted between 5% and 10% of participants in the orforglipron trial to cease their treatment regimen. This contrasts with the approximately 3% discontinuation rate observed in the group receiving the placebo.
According to a survey conducted by KFF, a non-profit health policy research organization, approximately one in every eight individuals in the United States has utilized injectable GLP-1 medications. Nevertheless, a significant proportion of the population struggles with the substantial financial burden associated with these highly priced treatments.
